Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Myc signaling, monocytes predict NSCLC response to second-line entinostat + pembro
- Author:
- Sharon Worcester
ATLANTA – Investigators have identified factors associated with response to combination entinostat and pembrolizumab among NSCLC patients who...
News
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
- Author:
- Sharon Worcester
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
News
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
- Author:
- Sharon Worcester
ATLANTA – Blood TMB predicts survival benefit in mNSCLC patients treated with first-line durvalumab plus tremelimumab versus chemo, according to...
News
Factors emerge for mitigating CD19 CAR T toxicity
- Author:
- Sharon Worcester
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
News
ENCORE-601: Entinostat/pembrolizumab safe, active for melanoma
- Author:
- Sharon Worcester
ATLANTA – Combined therapy with the HDAC inhibitor entinostat and the PD-1 inhibitor pembrolizumab has significant clinical activity and...
News
Novel CAR T, anti-PD-1 combo shows promise in MPD
- Author:
- Sharon Worcester
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
Video
Dr. Louis Weiner: AACR presentations highlight new “transformative strategies”
- Author:
- Sharon Worcester
ATLANTA – Studies featured during a press briefing at the AACR annual meeting, including work on a cancer preventive...
News
ACP: Average-risk women under 50 can postpone mammogram
- Author:
- Sharon Worcester
Reducing breast cancer overdiagnosis and overtreatment was a goal of the ACP guideline’s authors.
Video
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
- Author:
- Sharon Worcester
ATLANTA – Lynch syndrome is serving as a platform for the development of immunoprevention cancer vaccines.
Video
UNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZL
- Author:
- Sharon Worcester
ATLANTA – The phosphoinositide 3-kinase delta inhibitor is active as a single-agent therapy in patients with relapsed or refractory marginal zone...
News
Tisotumab vedotin shows promise in recurrent, metastatic cervical cancer
- Author:
- Sharon Worcester
The novel antibody-drug conjugate tisotumab vedotin (TV) shows encouraging activity and tolerability in heavily pretreated recurrent or metastatic...
News
Study explores third-line trabectedin plus PLD for BRCA1/2 ovarian cancer
- Author:
- Sharon Worcester
Adding trabectedin to PLD significantly prolonged OS and PFS in BRCA1/2 patients with advanced epithelial OC, according to a prespecified phase 3...
News
Study: Racial disparities in gyn-onc trial enrollment persist
- Author:
- Sharon Worcester
HONOLULU – A literature review shows that racial disparities in trial enrollment remain and may be increasing;...
News
ARIEL3 analysis: Rucaparib PFS benefit in recurrent OC occurs across age groups
- Author:
- Sharon Worcester
HONOLULU – The improved PFS seen with maintenance rucaparib vs. placebo in women with recurrent ovarian cancer in...
News
Neratinib shows promise in HER2-mutant cervical cancer
- Author:
- Sharon Worcester
HONOLULU – Treatment leads to durable responses and disease control in heavily pretreated metastatic patients with...